Strong financial results in Q1 2019
- Product sales revenue of €32.8 million in Q1 2019, representing 9% growth at constant exchange rate (CER)
- Significant growth in IXIARO® revenues (growth of 17% (CER)) in Q1 2019
- Total revenues were €34.9 million in Q1 2019
- EBITDA of €8.2 million in Q1 2019
- Net profit of €4.9 million in Q1 2019
- Positive operating cash flow of €5.3 million
- Strong cash position of €68.1 million at the end of March 2019
Two significant R&D milestones reported in Q1 2019
- Final Phase 1 data and first booster data for Lyme disease vaccine candidate, VLA15
- Positive Phase 1 interim results for chikungunya vaccine candidate, VLA1553